Polypharmacy in patients with advanced cancer and the role of medication discontinuation

The Lancet Oncology

Volumn 16, Issue 7, 2015, Pages e333-e341

  LeBlanc, Thomas W ^a,b,e   McNeil, Michael J ^d,e   Kamal, Arif H ^a,c,e   Currow, David C ^f   Abernethy, Amy P ^a,c,e  

^a DUKE CANCER INSTITUTE   (United States)

^b Department of Medicine   (United States)

^c Division of Medical Oncology   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ALTERNATIVE MEDICINE; AUSTRALIA; CANCER DIAGNOSIS; CANCER PATIENT; COMORBIDITY; DELIRIUM; DRUG WITHDRAWAL; GERIATRIC PATIENT; HOSPICE; HUMAN; LIFE EXPECTANCY; NURSING HOME; PALLIATIVE THERAPY; POLYPHARMACY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; ADVERSE DRUG REACTION; AGED; CASE CONTROL STUDY; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; FEMALE; GERIATRIC ASSESSMENT; MALE; MORTALITY; NEOPLASMS; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SURVIVAL; TERMINAL CARE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DRUG UTILIZATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; NEOPLASMS; POLYPHARMACY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TERMINAL CARE; TREATMENT OUTCOME;

EID: 84937394274     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00080-7     Document Type: Review

References (57)

1. Ferner RE, Aronson JK Communicating information about drug safety. BMJ 2006, 333:143-145.
2. Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001, 161:1629-1634.
3. Weng MC, Tsai CF, Sheu KL, et al. The impact of number of drugs prescribed on the risk of potentially inappropriate medication among outpatient older adults with chronic diseases. QJM 2013, 106:1009-1015.
4. Maddison AR, Fisher J, Johnston G Preventive medication use among persons with limited life expectancy. Prog Palliat Care 2011, 19:15-21.
5. Lees J, Chan A Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol 2011, 12:1249-1257.
6. Hajjar ER, Cafiero AC, Hanlon JT Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007, 5:345-351.
7. Fulton MM, Allen ER Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 2005, 17:123-132.
8. Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med 2011, 22:597-602.
9. Steinman MA, Hanlon JT Managing medications in clinically complex elders: "There's got to be a happy medium". JAMA 2010, 304:1592-1601.
10. Stevenson J, Abernethy AP, Miller C, Currow DC Managing comorbidities in patients at the end of life. BMJ 2004, 329:909-912.
11. Haddad A, Shepard D Geriatric oncology and palliative medicine. Semin Oncol 2011, 38:362-366.
12. Turner JP, Shakib S, Singhal N, et al. Prevalence and factors associated with polypharmacy in older people with cancer. Support Care Cancer 2014, 22:1727-1734.
13. Cashman J, Wright J, Ring A The treatment of co-morbidities in older patients with metastatic cancer. Support Care Cancer 2010, 18:651-655.
14. Fede A, Miranda M, Antonangelo D, et al. Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Support Care Cancer 2011, 19:1313-1318.
15. Jorgensen TLHJ, Friis S, Hallas J Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006. J Geriatr Oncol 2012, 3:33-40.
16. Kotlinska-Lemieszek A, Paulsen O, Kaasa S, Klepstad P Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients. J Pain Symptom Manage 2014, 48:1145-1159.
17. Maggiore RJ, Dale W, Gross CP, et al. Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc 2014, 62:1505-1512.
18. Puts MT, Costa-Lima B, Monette J, et al. Medication problems in older, newly diagnosed cancer patients in Canada: How common are they? A prospective pilot study. Drugs Aging 2009, 26:519-536.
19. Raijmakers NJ, van Zuylen L, Furst CJ, et al. Variation in medication use in cancer patients at the end of life: a cross-sectional analysis. Support Care Cancer 2013, 21:1003-1011.
20. Sokol KC, Knudsen JF, Li MM Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007, 32:169-175.
21. Todd A, Williamson S, Husband A, Baqir W, Mahony M Patients with advanced lung cancer: is there scope to discontinue inappropriate medication?. Int J Clin Pharm 2013, 35:181-184.
22. Currow DC, Stevenson JP, Abernethy AP, Plummer J, Shelby-James TM Prescribing in palliative care as death approaches. J Am Geriatr Soc 2007, 55:590-595.
23. Sera L, McPherson ML, Holmes HM Commonly prescribed medications in a population of hospice patients. Am J Hosp Palliat Care 2014, 31:126-131.
24. Lundy E, McMullan D, McShane P, Williams M, Watson M, White C Polypharmacy and drug omissions across hospices in Northern Ireland. J Palliat Med 2013, 16:1446-1449.
25. McLean S, Sheehy-Skeffington B, O'Leary N, O'Gorman A Pharmacological management of co-morbid conditions at the end of life: is less more?. Ir J Med Sci 2013, 182:107-112.
26. Nauck F, Ostgathe C, Klaschik E, et al. Drugs in palliative care: results from a representative survey in Germany. Palliat Med 2004, 18:100-107.
27. Russell BJ, Rowett D, Abernethy AP, Currow DC Prescribing for comorbid disease in a palliative population: focus on the use of lipid-lowering medications. Intern Med J 2014, 44:177-184.
28. O'Mahony D, O'Connor MN Pharmacotherapy at the end-of-life. Age Ageing 2011, 40:419-422.
29. Agar M, Currow D, Plummer J, Seidel R, Carnahan R, Abernethy AP Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliat Med 2009, 23:257-265.
30. Chan A, Tan SH, Wong CM, Yap KY, Ko Y Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. Clin Ther 2009, 31:2379-2386.
31. Ko Y, Tan SL, Chan A, et al. Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study. Clin Ther 2012, 34:1696-1704.
32. Popa MA, Wallace KJ, Brunello A, Extermann M, Balducci L Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol 2014, 5:307-314.
33. Van Leeuwen RW, Swart EL, Boom FA, Schuitenmaker MS, Hugtenburg JG Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method. BMC Cancer 2010, 10:679.
34. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010, 363:733-742.
35. Flood KL, Carroll MB, Le CV, Brown CJ Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology-acute care for elders unit. Am J Geriatr Pharmacother 2009, 7:151-158.
36. Kuhn-Thiel AM, Weiß C, Wehling M Consensus validation of the FORTA (Fit fOR The Aged) list: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging 2014, 31:131-140. for the FORTA authors/expert panel members.
37. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012, 60:616-631. American Geriatrics Society Beers Criteria Update Expert Panel.
38. Gallagher PF, O'Connor MN, O'Mahony D Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther 2011, 89:845-854.
39. Shrank WH, Polinski JM, Avorn J Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc 2007, 55(suppl 2):S373-S382.
40. LeBlanc TW, Kutner JS, Ritchie CS, Abernethy AP Discontinuation of statins in routine care settings. Ann Intern Med 2013, 159:74-75.
41. Garfinkel D, Mangin D Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med 2010, 170:1648-1654.
42. Garfinkel D, Zur-Gil S, Ben-Israel J The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J 2007, 9:430-434.
43. Suhrie EM, Hanlon JT, Jaffe EJ, Sevick MA, Ruby CM, Aspinall SL Impact of a geriatric nursing home palliative care service on unnecessary medication prescribing. Am J Geriatr Pharmacother 2009, 7:20-25.
44. Williams ME, Pulliam CC, Hunter R, et al. The short-term effect of interdisciplinary medication review on function and cost in ambulatory elderly people. J Am Geriatr Soc 2004, 52:93-98.
45. Kutner JS, Blatchford PJ, Taylor DH, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med 2015, 175:691-700.
46. Bayliss EA, Bronsert MR, Reifler LM, et al. Statin prescribing patterns in a cohort of cancer patients with poor prognosis. J Palliat Med 2013, 16:412-418.
47. Silveira MJ, Kazanis AS, Shevrin MP Statins in the last six months of life: a recognizable, life-limiting condition does not decrease their use. J Palliat Med 2008, 11:685-693.
48. Tanvetyanon T, Choudhury AM Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliat Care 2006, 22:281-285.
49. Lee SP, Bain KT, Maio V Appropriate discontinuation of medications at the end of life: a need to establish consensus criteria. Am J Med Qual 2007, 22:393-394.
50. Riechelmann RP, Krzyzanowska MK, Zimmermann C Futile medication use in terminally ill cancer patients. Support Care Cancer 2009, 17:745-748.
51. Abernethy AP, Aziz NM, Basch E, et al. A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group. J Palliat Med 2010, 13:1407-1413.
52. Leblanc TW, Kutner JS, Ko D, Wheeler JL, Bull J, Abernethy AP Developing the evidence base for palliative care: formation of the palliative care research cooperative and its first trial. Hosp Pract 2010, 38:137-143.
53. Holmes HM Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther 2009, 85:103-107.
54. Holmes HM, Hayley DC, Alexander GC, Sachs GA Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006, 166:605-609.
55. Lee SP, Bain KT, Maio V Appropriate discontinuation of medications at the end of life: a need to establish consensus criteria. Am J Med Qual 2007, 22:393-394.
56. Lindsay J, Dooley M, Martin J, Fay M, Kearney A, Barras M Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches. Support Care Cancer 2014, 22:1113-1119.
57. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010, 8:336-341.